



King's Research Portal

DOI:

[10.1177/0269881118798609](https://doi.org/10.1177/0269881118798609)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Freeman, T. P., Mehta, M. A., Neill, J. C., Nutt, D. J., Tunbridge, E. M., & Young, A. H. (2018). Restrictions on drugs with medical value: Moving beyond stalemate. *Journal of Psychopharmacology*, 32(10), Article 269881118798609. Advance online publication. <https://doi.org/10.1177/0269881118798609>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Journal of
Psychopharmacology

Restrictions on drugs with medical value: moving beyond stalemate

Journal:	<i>Journal of Psychopharmacology</i>
Manuscript ID	JOP-2018-3596
Manuscript Type:	Editorial
Date Submitted by the Author:	08-Aug-2018
Complete List of Authors:	Freeman, Tom; Institute of Psychiatry, Psychology & Neuroscience, National Addiction Centre; University of Bath, Department of Psychology Mehta, Mitul; Institute of Psychiatry, Centre for Neuroimaging Sciences Neill, Joanna; Manchester University, Manchester PHarmacy School Nutt, David; Imperial College , Neuropsychopharmacology Tunbridge, Elizabeth ; University of Oxford, Department of Psychiatry Young, Allan; Imperial College London, Centre for Mental Health
Please list at least 3 keywords which relate to your manuscript::	Schedule 1, Cannabis, MDMA, Psilocybin, British Association for Psychopharmacology
Abstract:	N/A

SCHOLARONE™
Manuscripts

Restrictions on drugs with medical value: moving beyond stalemate

Tom P Freeman^{1,2*}, Mitul A Mehta³, Joanna C Neill⁴, David J Nutt⁵, Elizabeth M Tunbridge⁶,
Allan H Young⁷

1. National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK
2. Department of Psychology, University of Bath, UK
3. Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK
4. Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester, UK
5. Neuropsychopharmacology Unit, Division of Brain Sciences, Imperial College London, London, UK
6. Department of Psychiatry, University of Oxford, and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
7. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK

*Address correspondence to:

Tom Freeman
National Addiction Centre
King's College London
4 Windsor Walk, London SE5 8BB
tom.freeman@kcl.ac.uk

Keywords: Schedule 1, Cannabis, MDMA, Psilocybin, British Association for
Psychopharmacology

1
2
3 A key task for psychopharmacology is to establish which medicines can provide optimal
4 clinical benefit with minimal levels of harm. Drugs that are considered to have no medical
5 value and a high risk of misuse or harm are listed in Schedule 1 of the UK Misuse of Drugs
6 Regulations 2001; these currently include cannabis, 3,4-methylenedioxymethamphetamine
7 (MDMA) and psilocybin. Schedule 1 drugs cannot be possessed or prescribed by clinicians,
8 and research is only permitted under a Home Office license that is costly and time intensive
9 to obtain.
10
11
12
13
14
15
16
17
18

19
20 By contrast, drugs that are deemed to have medical value despite a high liability for misuse or
21 harm are placed in Schedule 2, including diamorphine, cocaine, amphetamines and ketamine.
22 Research on these drugs is less restricted. They can be legally possessed by people with a
23 prescription and possessed and supplied by pharmacists, doctors and dentists. Restrictions are
24 lower still for drugs with widespread medical use listed in Schedules 3 to 5 such as
25 buprenorphine and diazepam. In light of accumulating evidence supporting the medical value
26 of Schedule 1 drugs including cannabis (Whiting et al., 2015), MDMA (Mithoefer et al.,
27 2018) and psilocybin (Ross et al., 2016), this legislation creates a barrier to research and the
28 advancement of medical science.
29
30
31
32
33
34
35
36
37
38
39
40

41 As part of a three-year commission from the Home Secretary, the Advisory Council for the
42 Misuse of Drugs (ACMD) has been engaged in consultations on how research using Schedule
43 1 drugs might be facilitated. Based on their initial consultations, several suggestions were
44 raised by the research community. These included a blanket exemption from Schedule 1 for
45 research (like the Psychoactive Substances Act 2016) or the provision of a single
46 organisational licence to bring exemption from Schedule 1 requirements for academic
47 institutions.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 To capture the views of the British Association for Psychopharmacology (BAP) in these
6 consultations, we conducted a survey in May 2018 on our members' experiences of
7 conducting research using controlled drugs. We received 23 detailed responses from
8 members with a range of backgrounds, including those in a clinical, preclinical and industrial
9 setting. Only two of these 23 respondents had no suggestions for improvement.
10
11

12
13
14
15 Overwhelmingly, our members consider that the current legislative framework requires
16 improvement to facilitate research. Specifically, Home Office licenses were reported to be
17 prohibitively costly (requiring both an initial and renewal fee, and highly specific and costly
18 requirements for storage). Furthermore, they were reported to create an unnecessary
19 administrative burden and significant delays that could not be scientifically justified, given
20 the low levels of risk compared to Schedule 2 drugs such as diamorphine (heroin).
21
22
23
24
25
26
27
28
29
30

31 To give specific examples, in some cases the Home Office had requested ethical approval
32 before granting an initial license; however, the relevant ethics committee had in turn
33 requested Home Office approval before accepting an application - a classic Catch 22 situation
34 - causing significant frustration, excess paperwork and long delays. From an industry
35 perspective, our members reported that opportunities to work internationally had to be
36 declined due to the excessive costs associated with the multiple import and export licenses
37 required under the current framework. The limited duration of import and export licences
38 raised further challenges. Our members suggested that research councils should be made
39 aware of these issues, as it may be necessary to request additional resources and time to
40 complete research studies. As one respondent put it: "*As it stands, it is so difficult to even
41 contemplate research in this area as you almost have to think 'Right, we might, if all goes
42 well, be able to start in 2 years.'*"
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Several respondents pointed out that the current system is unnecessarily burdensome for
6
7 researchers working with small quantities of Schedule 1 drugs. The Misuse of Drugs
8
9 Regulations 2001 lists an exemption for small quantities. However, apart from lysergide or
10
11 any other *N*-alkyl derivative of lysergamide (1 microgram) there is no drug-specific level of
12
13 exemption, and 1 milligram applies to all drugs. Problems were reported with obtaining a
14
15 small quantity of a cannabinoid (total 10mg delta-9-tetrahydrocannabinol), leading to
16
17 significant delay of a PhD student's submission and their supervisor, an Associate Professor
18
19 of psychiatry, deciding to abandon this line of research altogether: *"In short, I can tell you
20
21 without hesitation that the current legislation surrounding controlled drugs is stifling
22
23 research in this area: it has essentially dissuaded me from continuing my work. I no longer
24
25 work on controlled drugs."*

26
27
28
29
30
31 In contrast, experiences of working with Schedule 2 drugs were reported more favourably,
32
33 providing a potential framework for legislation moving forwards: *"We routinely use schedule
34
35 II drugs for experiments in animals. Process for ordering and management work well.
36
37 Schedule I drugs are much more difficult due to additional licensing which effectively
38
39 precludes use using these compounds despite potential value for preclinical research."*

40
41
42
43
44 Notably, the additional restrictions for Schedule 1 drugs was not considered scientific or
45
46 appropriate given the level of risk: *"The difference in regulations for using Schedule 2 drugs
47
48 e.g. PCP and Schedule 1 drugs e.g. cannabinoids, and difficulty in using Schedule 1 drugs is
49
50 not evidence based or scientific. The current UK drug laws are clearly hindering research at
51
52 all levels."* Although the ACMD initially considered that a blanket exemption of Schedule 1
53
54 restrictions for the research community would not be workable, feedback from our survey
55
56
57
58
59
60

1
2
3 highlighted that a similar exemption already exists, as University research departments are
4
5 not required to hold a Home Office license to possess and supply drugs in Schedules 2 to 5. It
6
7 was argued that extending this exemption to Schedule 1 should not be problematic or lead to
8
9 “unintended consequences”.

10
11
12
13
14 Shortly after our survey was completed, a high-profile case emerged in which a 12-year old
15
16 boy named Billy Caldwell and his mother travelled to Canada to obtain cannabis oil to
17
18 control his epileptic seizures. When they returned to the UK on June 11th 2018, the cannabis
19
20 oil was confiscated by the Home Office. The situation escalated when Billy was admitted to
21
22 hospital with severe and potentially life-threatening seizures, resulting in an unprecedented
23
24 decision from the Home Office to return the cannabis oil on June 16th. The Home Secretary,
25
26 Sajid Javid, commissioned a two-stage review on medicinal uses of cannabis products, and a
27
28 coalition of academics and clinicians led by several members of the BAP called on the
29
30 government remove them from Schedule 1.
31
32
33
34
35
36
37

38 The first stage of the review conducted by Chief Medical Officer Sally Davis stated: *“There*
39
40 *is now however, conclusive evidence of the therapeutic benefit of cannabis based medicinal*
41
42 *products for certain medical conditions and reasonable evidence of therapeutic benefit in*
43
44 *several other medical conditions... As Schedule 1 drugs by definition have little or no*
45
46 *therapeutic potential, it is therefore now clear that from a scientific point of view keeping*
47
48 *cannabis based medicinal products in Schedule 1 is very difficult to defend.”* The second
49
50 stage of the review conducted by the ACMD agreed with this conclusion, recommending that
51
52 cannabis-derived medicinal products (once clearly defined) should be moved from Schedule
53
54 1 to Schedule 2.
55
56
57

1
2
3
4
5
6 Home Secretary announced on 26th July 2018 that cannabis-derived medical products would
7
8 be moved Schedule 2. He should be commended for rapidly commissioning these two
9
10 reviews, and for informing his decision using scientific evidence. This historical move broke
11
12 the longstanding and illogical stalemate of holding drugs with medical value in Schedule 1.
13
14 In their commissioned review, the ACMD also concluded that: "*it is important that cannabis*
15
16 *is not seen in isolation but as an example of a wider issue of potential 'barriers to research'*
17
18 *associated with other drugs in Schedule 1.*" In light of the efficiency with which cannabis
19
20 products were reviewed - and the clear conclusions reached - we now hope that scientific
21
22 evidence and review can challenge the Schedule 1 status of other potential medicines,
23
24 including MDMA and psilocybin.
25
26

27
28 In conclusion, the results of our survey clearly demonstrate that current UK legislation
29
30 hampers research into the consequences, and potential therapeutic benefits of Schedule 1
31
32 drugs. We praise the government's rapid response to cannabis based-medicinal products, and
33
34 hope this will encourage further debate about the Misuse of Drugs Regulations and its impact
35
36 on the field of psychopharmacology.
37
38

39
40 Acknowledgements: TF was funded by a senior academic fellowship from the Society for the
41
42 Study of Addiction (SSA). AY was funded by the National Institute for Health Research
43
44 (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
45
46 and King's College London. The views expressed are those of the authors and not necessarily
47
48 those of the SSA, NHS, the NIHR, or the Department of Health.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Conflicts of interest: All authors are officers or council members of the British Association
4 for Psychopharmacology (BAP). For a regularly updated list of their declarations of interest,
5 please refer to the BAP website: <https://www.bap.org.uk/council.php>
6
7
8
9

10 Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., . . .
11 Emerson, A. (2018). 3, 4-methylenedioxymethamphetamine (MDMA)-assisted
12 psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and
13 police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. *The*
14 *Lancet Psychiatry*, 5(6), 486-497.

15
16 Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., . . . Babb, J. (2016).
17 Rapid and sustained symptom reduction following psilocybin treatment for anxiety
18 and depression in patients with life-threatening cancer: a randomized controlled trial.
19 *Journal of Psychopharmacology*, 30(12), 1165-1180.

20 Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., . . .
21 Ryder, S. (2015). Cannabinoids for medical use: a systematic review and meta-
22 analysis. *JAMA*, 313(24), 2456-2473.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60